- Home
- ELVN vs AB Comparison
ELVN vs AB Comparison
Compare ELVN & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELVN | AB |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ELVN | AB |
|---|---|---|
| Price | $57.95 | $36.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $43.40 | $40.40 |
| AVG Volume (30 Days) | ★ 1.0M | 278.1K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 8.59% |
| EPS Growth | ★ 3.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.45 |
| P/E Ratio | ★ N/A | $13.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.79 | $34.92 |
| 52 Week High | $62.32 | $44.11 |
Technical Indicators
Market Signals| Indicator | ELVN | AB |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 53.50 |
| Support Level | $56.69 | $35.96 |
| Resistance Level | $62.32 | $37.69 |
| Average True Range (ATR) | 1.92 | 0.53 |
| MACD | -0.28 | 0.05 |
| Stochastic Oscillator | 57.25 | 71.64 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (41%), and private (18%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of February 2026, the company had $880.0 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (40%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.